Go Pro
→ SpaceX pays a 10X launch penalty (From Freedom Financial) (Ad)tc pixel Free CELU Stock Alerts

Celularity (CELU) Financials

Celularity logo
$0.75 +0.00 (+0.13%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$0.76 +0.01 (+1.60%)
As of 07/27/2026 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Celularity

Annual Income Statements for Celularity

This table shows Celularity's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 5.88 -208 -100 14 -193 -58 -92
Consolidated Net Income / (Loss)		 5.88 -208 -100 14 -196 -58 -92
Net Income / (Loss) Continuing Operations		 5.88 -208 -100 14 -193 -58 -92
Total Pre-Tax Income 		6.55 -213 -100 14 -196 -58 -92
Total Revenue		 3.75 -4.43 0.00 0.00 0.00 0.00 0.00
Net Interest Income / (Expense)		 3.75 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Income		 3.75 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Non-Interest Income		 -0.01 -4.43 0.00 0.00 0.00 0.00 0.00
Total Non-Interest Expense		 1.68 211 109 26 189 48 70
Marketing Expense		 - 53 88 78 30 17 15
Other Operating Expenses		 - 95 81 86 66 83 81
Amortization Expense		 - 3.39 2.19 2.19 2.19 1.75 1.49
Restructuring Charge		 - -56 -41 -126 - -0.19 0.00
Other Special Charges		 1.68 -14 -21 -18 -23 -54 -27
Nonoperating Income / (Expense), net		 4.49 2.11 8.96 40 -4.00 -9.94 -21
Income Tax Expense		 0.67 -4.70 0.02 0.01 0.01 0.00 0.00
Preferred Stock Dividends Declared		 - - - - - 0.00 0.08
Basic Earnings per Share		 $0.47 ($11.31) ($1.49) $1.01 ($11.02) ($2.64) ($3.59)
Weighted Average Basic Shares Outstanding		 9.09M 18.42M 67.06M 13.99M 17.81M 21.89M 25.60M
Diluted Earnings per Share		 $0.47 ($11.31) ($1.49) $0.95 ($11.02) ($2.64) ($3.59)
Weighted Average Diluted Shares Outstanding		 9.09M 18.42M 67.06M 14.98M 17.81M 21.89M 25.60M

Quarterly Income Statements for Celularity

This table shows Celularity's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -94 11 -22 -6.49 -16 -13 -20 -25 -23 -24
Consolidated Net Income / (Loss)		 -94 9.55 -22 -6.49 -16 -13 -20 -25 -23 -24
Net Income / (Loss) Continuing Operations		 -94 11 -20 -6.03 -16 -16 -20 -24 -20 -28
Total Pre-Tax Income 		-94 9.56 -22 -6.49 -16 -13 -30 -25 -23 -14
Total Revenue		 0.00 -3.94 15 0.00 0.00 -15 17 0.00 0.00 -17
Total Non-Interest Income		 0.00 -3.94 15 0.00 0.00 -15 17 0.00 0.00 -17
Total Non-Interest Expense		 99 -21 20 9.72 11 6.67 28 15 13 15
Marketing Expense		 5.18 -0.27 5.84 3.80 3.92 3.83 3.73 3.35 4.60 3.35
Other Operating Expenses		 15 0.10 14 18 17 35 24 18 13 26
Other Special Charges		 -3.79 - - -12 -9.30 - -0.24 -5.74 -5.28 -15
Nonoperating Income / (Expense), net		 5.38 -3.76 -15 3.69 -4.57 5.59 -9.27 -8.66 -7.27 3.98
Income Tax Expense		 0.00 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($4.98) $0.63 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95)
Weighted Average Basic Shares Outstanding		 18.83M 17.81M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M
Diluted Earnings per Share		 ($4.98) $0.63 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95)
Weighted Average Diluted Shares Outstanding		 18.83M 17.81M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M
Basic & Diluted Earnings per Share		 - $0.63 - - - ($0.61) - - - ($0.95)
Weighted Average Basic & Diluted Shares Outstanding		 - 0.00 - - 22.48M 0.00 - 26.69M 28.33M 0.00

Annual Cash Flow Statements for Celularity

This table details how cash moves in and out of Celularity's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.89 26 -17 -23 -19 0.81 5.40
Net Cash From Operating Activities		 -1.10 -63 -110 -138 -39 -6.40 -13
Net Cash From Continuing Operating Activities		 -1.10 -63 -110 -138 -39 -6.40 -13
Net Income / (Loss) Continuing Operations		 5.88 -208 -100 14 -196 -58 -92
Consolidated Net Income / (Loss)		 5.88 -208 -100 14 -196 -58 -92
Provision For Loan Losses		 - 0.29 0.30 1.88 1.23 0.46 1.35
Depreciation Expense		 - 8.17 8.82 9.44 9.32 7.92 7.30
Amortization Expense		 - 0.06 - - - 0.00 -1.91
Non-Cash Adjustments to Reconcile Net Income		 -7.11 137 -9.28 -145 140 21 38
Changes in Operating Assets and Liabilities, net		 0.14 -0.09 -9.81 -18 7.41 23 34
Net Cash From Investing Activities		 -287 -13 -5.90 -5.24 -4.05 0.51 0.00
Net Cash From Continuing Investing Activities		 -287 -13 -5.90 -5.24 -4.05 0.51 0.00
Purchase of Property, Leasehold Improvements and Equipment		 - -28 -6.20 -5.24 -1.05 -0.16 0.00
Purchase of Investment Securities		 -288 - - 0.00 -3.00 -1.50 0.00
Sale and/or Maturity of Investments		 - 0.00 0.30 - 0.00 2.18 0.00
Net Cash From Financing Activities		 289 102 99 120 24 6.70 19
Net Cash From Continuing Financing Activities		 289 102 99 120 24 6.70 19
Issuance of Debt		 0.13 0.00 5.00 86 20 19 20
Issuance of Preferred Equity		 - 103 - - - 6.00 2.00
Issuance of Common Equity		 7.00 0.00 83 37 22 0.00 1.04
Repayment of Debt		 -0.28 -0.40 -16 -2.60 -18 -18 -8.65
Other Financing Activities, Net		 282 0.14 26 0.23 0.20 -0.40 4.17
Cash Interest Paid		 - 0.00 0.15 0.00 1.07 0.14 2.50
Cash Income Taxes Paid		 0.65 0.01 0.00 0.00 - 0.00 0.05

Quarterly Cash Flow Statements for Celularity

This table details how cash moves in and out of Celularity's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -2.81 -4.94 1.79 -1.39 -0.22 0.65 -0.67 0.63 -0.68 6.12
Net Cash From Operating Activities		 -8.32 -4.34 -4.40 -3.45 -0.14 1.59 -2.99 -1.00 -4.16 -5.10
Net Cash From Continuing Operating Activities		 -8.32 -4.34 -4.40 -3.45 -0.14 1.59 -2.99 -1.00 -4.16 -5.10
Net Income / (Loss) Continuing Operations		 -94 9.55 -22 -6.49 -16 -13 -20 -25 -23 -24
Consolidated Net Income / (Loss)		 -94 9.55 -22 -6.49 -16 -13 -20 -25 -23 -24
Provision For Loan Losses		 0.08 0.78 0.20 0.11 -0.08 0.24 -0.06 0.01 -0.10 1.50
Depreciation Expense		 2.34 2.30 2.16 2.00 1.89 1.88 1.83 1.83 1.82 1.80
Amortization Expense		 - - - - - - - - - -1.86
Non-Cash Adjustments to Reconcile Net Income		 80 12 17 -6.12 7.11 2.44 11 6.92 11 9.91
Changes in Operating Assets and Liabilities, net		 2.95 -29 -1.93 7.06 7.03 10 4.29 15 6.65 7.91
Net Cash From Financing Activities		 5.74 -0.01 6.23 -0.09 -0.08 0.64 2.32 1.63 3.48 11
Net Cash From Continuing Financing Activities		 5.74 -0.01 6.23 -0.09 -0.08 0.64 2.32 1.63 3.48 11
Issuance of Debt		 3.00 - 18 - - 0.63 0.00 - 9.10 11
Issuance of Common Equity		 3.00 - 6.00 - - -6.00 2.46 1.01 -0.44 -2.00
Repayment of Debt		 -0.26 - -17 -0.12 0.02 -0.04 -0.04 -0.26 -6.78 -1.57
Other Financing Activities, Net		 -0.00 -0.01 -0.38 0.03 -0.10 0.05 -0.10 0.88 1.60 1.79
Cash Interest Paid		 - - 0.00 0.14 - - 0.00 - 1.77 0.73

Annual Balance Sheets for Celularity

This table presents Celularity's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.17 292 431 414 401 144 133 107
Cash and Due from Banks		 0.02 0.92 54 37 14 0.23 0.74 6.18
Restricted Cash		 - - 15 15 15 9.94 10 10
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 - - 90 91 76 68 62 56
Goodwill		 - - 123 123 120 7.35 7.35 7.35
Intangible Assets		 - - 125 123 121 11 9.25 7.76
Other Assets		 0.00 291 23 25 56 48 44 20
Total Liabilities & Shareholders' Equity		 0.17 292 431 414 401 144 133 107
Total Liabilities		 0.15 28 412 315 202 103 124 145
Short-Term Debt		 0.00 0.02 5.39 9.32 43 53 30 43
Accrued Interest Payable		 - - 13 12 16 11 20 33
Other Short-Term Payables		 0.15 0.21 7.84 5.25 2.27 2.83 3.53 5.65
Long-Term Debt		 - - 28 28 0.00 0.00 36 0.00
Other Long-Term Liabilities		 0.00 28 358 260 140 36 34 65
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 5.00 -531 99 199 41 8.84 -38
Total Preferred & Common Equity		 0.02 5.00 -531 99 199 41 8.84 -38
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.02 5.00 -531 99 199 41 8.84 -38
Common Stock		 0.03 1.12 32 763 844 883 909 953
Retained Earnings		 -0.00 3.88 -564 -664 -645 -842 -900 -991
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.01 0.00 -0.01 0.00

Quarterly Balance Sheets for Celularity

This table presents Celularity's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 157 144 135 129 129 120 114
Cash and Due from Banks		 0.27 1.90 0.47 0.13 0.29 0.86 0.12
Restricted Cash		 15 10 10 10 10 10 10
Trading Account Securities		 - - - - - - 2.89
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 71 66 65 63 60 59 57
Goodwill		 7.35 7.35 7.35 7.35 7.35 7.35 7.35
Intangible Assets		 12 10 10.00 9.62 8.88 8.51 8.13
Other Assets		 53 48 43 38 42 35 28
Total Liabilities & Shareholders' Equity		 157 144 135 129 129 120 114
Total Liabilities		 127 113 108 112 134 146 134
Short-Term Debt		 48 53 55 58 30 31 30
Accrued Interest Payable		 34 10 10 14 25 33 29
Other Short-Term Payables		 2.46 2.81 2.79 3.69 3.48 3.50 5.58
Long-Term Debt		 - - 0.00 0.00 36 36 0.00
Other Long-Term Liabilities		 42 47 40 35 39 40 69
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 30 31 28 17 -5.51 -25 -20
Total Preferred & Common Equity		 30 31 28 17 -5.51 -25 -20
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 30 31 28 17 -5.51 -25 -20
Common Stock		 879 895 898 904 914 919 947
Retained Earnings		 -851 -864 -870 -886 -920 -944 -967
Accumulated Other Comprehensive Income / (Loss)		 2.40 - - -0.00 0.00 -0.00 0.00

Annual Metrics And Ratios for Celularity

This table displays calculated financial ratios and metrics derived from Celularity's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 35,937,500.00 35,937,500.00 123,464,113.00 145,013,313.00 193,781,641.00 22,484,239.00 28,328,880.00
DEI Adjusted Shares Outstanding		 3,593,750.00 3,593,750.00 12,346,411.00 14,501,331.00 19,378,164.00 22,484,239.00 28,328,880.00
DEI Earnings Per Adjusted Shares Outstanding		 1.64 -57.94 -8.11 0.98 -10.13 -2.57 -3.24
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -218.38% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -10,129.78% 51.53% 83.88% -1,010.22% 77.68% -62.59%
EBIT Growth		 0.00% -10,528.95% 49.29% 76.53% -637.29% 74.58% -46.96%
NOPAT Growth		 0.00% -8,230.08% 49.29% 66.50% -426.27% 75.06% -46.98%
Net Income Growth		 0.00% -3,642.12% 51.92% 114.18% -1,483.14% 70.51% -58.43%
EPS Growth		 0.00% -2,506.38% 86.83% 114.18% -1,483.14% 76.04% -35.98%
Operating Cash Flow Growth		 0.00% -5,656.16% -74.22% -25.23% 71.94% 83.45% -107.06%
Free Cash Flow Firm Growth		 0.00% 0.00% -364.01% 18.80% 110.20% -202.08% 250.97%
Invested Capital Growth		 0.00% -80.36% 164.45% 77.10% -61.07% -21.12% -93.99%
Revenue Q/Q Growth		 0.00% 0.00% 100.00% 0.00% -100.00% -100.00% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% 60.85% 66.20% 0.11% -3,628.12% -51.16%
EBIT Q/Q Growth		 0.00% 0.00% 58.70% 55.42% 0.18% -409.37% -39.75%
NOPAT Q/Q Growth		 0.00% 0.00% 58.70% 37.04% -2.22% -204.24% -7.08%
Net Income Q/Q Growth		 0.00% 0.00% 60.31% 199.37% -8.21% -65.16% -13.73%
EPS Q/Q Growth		 0.00% 0.00% 37.13% 199.37% -8.21% -73.68% -22.95%
Operating Cash Flow Q/Q Growth		 0.00% -35.65% -16.03% 1.75% 39.49% 48.11% -102.14%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -7.38% 370.40% -67.61% 8.46%
Invested Capital Q/Q Growth		 0.00% 0.00% 4.23% 13.92% 20.67% -1.15% -56.18%
Profitability Metrics		 - - - - - - -
EBITDA Margin		 55.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 55.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 156.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 89.79% 97.79% 100.02% 99.91% 100.01% 100.00% 100.00%
Interest Burden Percent		 317.51% 99.02% 91.78% -55.51% 104.03% 120.70% 130.12%
Effective Tax Rate		 10.21% 0.00% 0.00% 0.09% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 21,327.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 1.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2.23% -147.63% -169.50% 9.51% -163.67% -232.51% 627.65%
Cash Return on Invested Capital (CROIC)		 0.00% 38.80% -171.22% -69.14% 7.94% -16.17% 52.23%
Operating Return on Assets (OROA)		 1.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 4.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.04% 275.47% 619.84% 9.51% -163.67% -232.51% 627.65%
Return on Equity Simple (ROE_SIMPLE)		 117.59% 39.19% -100.70% 7.14% -479.24% -655.11% 240.96%
Net Operating Profit after Tax (NOPAT)		 1.85 -151 -76 -26 -135 -34 -49
NOPAT Margin		 49.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -21,327.29% 349.25% 67.52% -98.42% 127.47% 40.89% 78.38%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 44.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 2.06 -215 -109 -26 -189 -48 -70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.06 -207 -100 -16 -179 -40 -65
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 71.53 0.00 6.36 0.94 1.15 5.29 0.00
Price to Tangible Book Value (P/TBV)		 71.53 0.00 0.00 0.00 2.09 0.00 0.00
Price to Revenue (P/Rev)		 95.47 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 60.83 0.00 0.00 13.18 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.64% 0.00% 0.00% 7.59% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.34 17.57 4.51 0.83 0.96 1.36 12.87
Enterprise Value to Revenue (EV/Rev)		 164.22 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 298.29 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 298.29 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 332.20 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 14.87 0.00 0.00 6.77 0.00 2.80
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 1.76 0.38 0.22 1.30 7.42 -1.12
Long-Term Debt to Equity		 0.00 1.48 0.28 0.00 0.00 4.07 0.00
Financial Leverage		 0.00 0.12 0.60 0.27 0.40 2.39 -3.70
Leverage Ratio		 1.11 2.56 7.15 2.73 2.27 5.55 -8.21
Compound Leverage Factor		 3.52 2.54 6.57 -1.52 2.36 6.70 -10.69
Debt to Total Capital		 0.01% 63.83% 27.34% 17.92% 56.58% 88.13% 950.36%
Short-Term Debt to Total Capital		 0.01% 10.42% 6.81% 17.92% 56.58% 39.85% 950.36%
Long-Term Debt to Total Capital		 0.00% 53.41% 20.53% 0.00% 0.00% 48.28% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 98.09% 1,063.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 1.90% -1,027.12% 72.66% 82.08% 43.42% 11.87% -850.36%
Debt to EBITDA		 0.01 -0.16 -0.37 -2.69 -0.30 -1.64 -0.65
Net Debt to EBITDA		 -0.44 0.18 0.15 -0.90 -0.24 -1.36 -0.40
Long-Term Debt to EBITDA		 0.00 -0.13 -0.28 0.00 0.00 -0.90 0.00
Debt to NOPAT		 0.01 -0.22 -0.49 -1.70 -0.40 -1.95 -0.86
Net Debt to NOPAT		 -0.49 0.24 0.19 -0.57 -0.32 -1.63 -0.53
Long-Term Debt to NOPAT		 0.00 -0.18 -0.37 0.00 0.00 -1.07 0.00
Noncontrolling Interest Sharing Ratio		 98.09% 286.60% 465.68% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 61 -161 -131 13 -14 21
Operating Cash Flow to CapEx		 0.00% -227.04% -1,774.88% -2,633.23% -3,691.32% -3,975.78% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 263 52 137 242 94 74 4.48
Invested Capital Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -212 85 105 -148 -20 -70
Enterprise Value (EV)		 615 909 617 202 90 101 58
Market Capitalization		 358 395 632 187 47 47 31
Book Value per Share		 $0.14 ($14.79) $0.81 $1.37 $0.21 $0.39 ($1.34)
Tangible Book Value per Share		 $0.14 ($21.71) ($1.19) ($0.29) $0.12 ($0.35) ($1.88)
Total Capital		 263 52 137 242 94 74 4.48
Total Debt		 0.02 33 37 43 53 66 43
Total Long-Term Debt		 0.00 28 28 0.00 0.00 36 0.00
Net Debt		 -0.90 -36 -15 15 43 55 26
Capital Expenditures (CapEx)		 0.00 28 6.20 5.24 1.05 0.16 0.00
Net Nonoperating Expense (NNE)		 -4.03 58 24 -40 62 24 42
Net Nonoperating Obligations (NNO)		 0.02 33 37 43 53 66 43
Total Depreciation and Amortization (D&A)		 0.00 8.23 8.82 9.44 9.32 7.92 5.38
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 ($0.30) $0.00 ($14.90) $1.00 ($11.02) ($2.64) ($3.59)
Adjusted Weighted Average Basic Shares Outstanding		 3.59M 0.00 13.77M 13.99M 17.81M 21.89M 25.60M
Adjusted Diluted Earnings per Share		 ($0.30) $0.00 ($14.90) $0.90 ($11.02) ($2.64) ($3.59)
Adjusted Weighted Average Diluted Shares Outstanding		 3.59M 0.00 13.77M 14.98M 17.81M 21.89M 25.60M
Adjusted Basic & Diluted Earnings per Share		 ($0.30) $0.00 ($14.90) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 801.54K 0.00 6.71M 16.50M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 3.36 -109 -120 -166 -72 -72 -68
Normalized NOPAT Margin		 89.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 174.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.12% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Celularity

This table displays calculated financial ratios and metrics derived from Celularity's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 190,948,190.00 193,781,641.00 193,781,641.00 193,781,641.00 21,984,614.00 22,484,239.00 22,484,239.00 23,949,229.00 26,691,477.00 28,328,880.00
DEI Adjusted Shares Outstanding		 19,094,819.00 19,378,164.00 19,378,164.00 19,378,164.00 21,984,614.00 22,484,239.00 22,484,239.00 23,949,229.00 26,691,477.00 28,328,880.00
DEI Earnings Per Adjusted Shares Outstanding		 -4.92 0.49 -1.14 -0.33 -0.73 -0.59 -0.88 -1.02 -0.86 -0.86
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 273.09% 0.00% 0.00% -273.09% 17.10% 0.00% 0.00% -17.10%
EBITDA Growth		 -3,113.30% 0.98% 94.18% 80.89% 90.45% -199.96% -141.20% -76.85% -15.58% -64.57%
EBIT Growth		 -1,734.68% 1.97% 91.02% 77.26% 88.76% -224.22% -82.51% -59.40% -12.30% -49.84%
NOPAT Growth		 -1,126.23% -23.89% 88.45% 76.05% 88.39% -199.36% -184.33% -55.91% -37.10% 5.46%
Net Income Growth		 -2,056.16% -60.93% 65.61% 86.47% 82.85% -239.24% 10.26% -277.99% -43.35% -83.27%
EPS Growth		 -2,056.16% -60.93% 75.00% 88.97% 85.34% -196.83% 18.45% -240.00% -20.55% -55.74%
Operating Cash Flow Growth		 77.94% 85.33% 70.64% 68.73% 98.27% 136.72% 32.02% 71.03% -2,788.19% -420.14%
Free Cash Flow Firm Growth		 174.68% 283.22% 176.76% 320.02% -107.96% -95.84% -92.43% -61.28% 1,143.33% 756.49%
Invested Capital Growth		 -63.24% -61.07% -58.00% -49.92% -3.70% -21.12% -27.46% -48.70% -86.43% -93.99%
Revenue Q/Q Growth		 0.00% 0.00% 473.09% -100.00% 0.00% 0.00% 217.10% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -139.75% 120.11% -118.37% -115.73% -19.88% -110.40% -13.62% -58.17% 21.66% -199.59%
EBIT Q/Q Growth		 -132.20% 117.32% -133.37% -69.44% -14.74% -91.49% -10.48% -47.98% 19.16% -155.50%
NOPAT Q/Q Growth		 -133.68% 119.14% -138.82% -37.95% -13.29% -63.78% -59.02% 24.36% 0.38% -12.94%
Net Income Q/Q Growth		 -95.78% 110.17% -330.58% 70.53% -148.12% 17.42% -48.60% -24.15% 5.90% -5.57%
EPS Q/Q Growth		 -95.78% 110.17% -263.49% 70.87% -143.33% 16.44% -64.71% -21.43% 13.73% -7.95%
Operating Cash Flow Q/Q Growth		 24.53% 47.84% -1.43% 21.69% 95.82% 1,206.94% -287.77% 66.62% -316.32% -22.70%
Free Cash Flow Firm Q/Q Growth		 290.47% 147.94% -31.25% -32.24% -106.89% 229.57% -21.47% 246.51% 85.67% 6.37%
Invested Capital Q/Q Growth		 -52.56% 20.67% -10.93% -1.78% -8.78% -1.15% -18.10% -30.54% -75.87% -56.18%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 0.00% 0.00% -24.39% 0.00% 0.00% 0.00% -50.23% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% -39.07% 0.00% 0.00% 0.00% -60.89% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -149.94% 0.00% 0.00% 0.00% -114.90% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.90% 100.00% 100.00% 100.00% 100.00% 65.32% 100.00% 100.00% 175.61%
Interest Burden Percent		 94.58% 55.59% 383.77% 66.76% 144.35% 62.25% 288.85% 158.30% 184.25% 43.35%
Effective Tax Rate		 0.00% 0.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -2.66% 0.00% 0.00% 0.00% -2.96% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -37.32% 0.00% 0.00% 0.00% -11.47% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -19.42% 0.00% 0.00% 0.00% -53.13% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -163.67% -22.08% 0.00% 0.00% -232.51% -56.08% 0.00% 0.00% 627.65%
Cash Return on Invested Capital (CROIC)		 1.95% 7.94% 14.78% 7.93% -10.61% -16.17% -22.11% -4.63% 44.43% 52.23%
Operating Return on Assets (OROA)		 0.00% 0.00% -1.66% 0.00% 0.00% 0.00% -1.12% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -6.37% 0.00% 0.00% 0.00% -2.12% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -163.67% -22.08% 0.00% 0.00% -232.51% -56.08% 0.00% 0.00% 627.65%
Return on Equity Simple (ROE_SIMPLE)		 -599.76% 0.00% -493.81% -405.70% -202.85% 0.00% 1,010.41% 288.93% 401.35% 0.00%
Net Operating Profit after Tax (NOPAT)		 -69 13 -5.16 -7.12 -8.07 -13 -15 -11 -11 -12
NOPAT Margin		 0.00% 0.00% -35.17% 0.00% 0.00% 0.00% -85.39% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 50.61% 7.76% 34.66% -1.26% 15.16% 0.13% 8.51% 21.90% 27.20% 21.95%
SG&A Expenses to Revenue		 0.00% 0.00% 39.80% 0.00% 0.00% 0.00% 21.68% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 139.07% 0.00% 0.00% 0.00% 160.89% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -99 17 -5.74 -9.72 -11 -21 -10 -15 -13 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -97 19 -3.58 -7.72 -9.26 -19 -8.64 -14 -11 -32
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.40 1.15 3.24 2.18 3.78 5.29 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.74 2.09 7.54 5.80 211.31 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 10.78 0.00 9.43 5.64 6.08 0.00 15.49 18.69 22.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.96 0.96 1.69 1.27 1.50 1.36 1.56 2.45 7.37 12.87
Enterprise Value to Revenue (EV/Rev)		 19.12 0.00 13.23 9.75 10.52 0.00 37.85 41.35 29.99 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 26.48 6.77 6.77 10.68 0.00 0.00 0.00 0.00 3.96 2.80
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.58 1.30 1.69 1.97 3.36 7.42 -12.07 -2.66 -1.51 -1.12
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 4.07 -6.63 -1.43 0.00 0.00
Financial Leverage		 0.50 0.40 0.52 0.69 2.23 2.39 4.63 52.97 -31.39 -3.70
Leverage Ratio		 3.06 2.27 2.71 2.61 6.02 5.55 10.59 110.53 -86.38 -8.21
Compound Leverage Factor		 2.89 1.26 10.40 1.74 8.69 3.46 30.60 174.98 -159.16 -3.56
Debt to Total Capital		 61.31% 56.58% 62.82% 66.30% 77.05% 88.13% 109.03% 160.22% 296.71% 950.36%
Short-Term Debt to Total Capital		 61.31% 56.58% 62.82% 66.30% 77.05% 39.85% 49.16% 74.03% 296.71% 950.36%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 48.28% 59.87% 86.19% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 38.69% 43.42% 37.18% 33.70% 22.95% 11.87% -9.03% -60.22% -196.71% -850.36%
Debt to EBITDA		 -0.27 -0.30 -0.43 -0.62 -54.01 -1.64 -1.86 -1.63 -0.70 -0.65
Net Debt to EBITDA		 -0.18 -0.24 -0.34 -0.50 -44.43 -1.36 -1.57 -1.37 -0.47 -0.40
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.90 -1.02 -0.88 0.00 0.00
Debt to NOPAT		 -0.36 -0.40 -0.56 -0.76 -5.26 -1.95 -1.70 -1.57 -0.66 -0.86
Net Debt to NOPAT		 -0.25 -0.32 -0.43 -0.61 -4.32 -1.63 -1.44 -1.32 -0.44 -0.53
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -1.07 -0.93 -0.85 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 65 161 111 75 -5.18 6.71 8.40 29 54 57
Operating Cash Flow to CapEx		 -3,650.00% -748.45% -11,289.74% -11,122.58% 0.00% 1,751.65% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.04 0.06 0.08 0.00 0.02 0.02 0.02 0.00
Fixed Asset Turnover		 0.05 0.00 0.15 0.16 0.16 0.00 0.04 0.04 0.04 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 78 94 84 83 75 74 61 42 10 4.48
Invested Capital Turnover		 0.03 0.00 0.08 0.09 0.14 0.00 0.03 0.04 0.06 0.00
Increase / (Decrease) in Invested Capital		 -135 -148 -116 -82 -2.89 -20 -23 -40 -65 -70
Enterprise Value (EV)		 75 90 142 105 113 101 95 104 75 58
Market Capitalization		 42 47 101 61 65 47 39 47 55 31
Book Value per Share		 $0.16 $0.21 $0.16 $0.14 $0.79 $0.39 ($0.24) ($1.06) ($0.75) ($1.34)
Tangible Book Value per Share		 $0.06 $0.12 $0.07 $0.05 $0.01 ($0.35) ($0.97) ($1.72) ($1.33) ($1.88)
Total Capital		 78 94 84 83 75 74 61 42 10 4.48
Total Debt		 48 53 53 55 58 66 66 68 30 43
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 36 36 36 0.00 0.00
Net Debt		 33 43 41 44 48 55 56 57 20 26
Capital Expenditures (CapEx)		 0.23 0.58 0.04 0.03 0.00 0.09 0.00 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 24 3.75 17 -0.63 8.03 0.08 5.07 13 12 12
Net Nonoperating Obligations (NNO)		 48 53 53 55 58 66 66 68 30 43
Total Depreciation and Amortization (D&A)		 2.34 2.30 2.16 2.00 1.89 1.88 1.83 1.83 1.82 -0.06
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.00) $6.30 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95)
Adjusted Weighted Average Basic Shares Outstanding		 18.83M 1.78M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M
Adjusted Diluted Earnings per Share		 ($5.00) $6.30 ($1.03) ($0.30) ($0.73) ($0.61) ($0.84) ($1.02) ($0.88) ($0.95)
Adjusted Weighted Average Diluted Shares Outstanding		 18.83M 1.78M 21.44M 21.85M 21.98M 21.89M 23.53M 24.02M 26.35M 25.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $6.30 $0.00 $0.00 $0.00 ($0.61) $0.00 $0.00 $0.00 ($0.95)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 22.48M 0.00 0.00 26.69M 28.33M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -94 -5.16 -16 -15 -13 -15 -15 -15 -23
Normalized NOPAT Margin		 0.00% 0.00% -35.17% 0.00% 0.00% 0.00% -86.38% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -149.94% 0.00% 0.00% 0.00% -175.90% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Celularity’s latest results show a company still under heavy financial strain, but with some improvement in cash generation and a more stable balance sheet than a year ago. Revenue in Q4 2025 was negative in the data provided, which suggests unusual accounting items or a highly distorted reporting period, while the company continued to post significant losses. At the same time, operating cash burn improved modestly versus some earlier quarters, and the balance sheet now shows less leverage than mid-2025.

  • Leverage improved materially from mid-2025. Total liabilities fell to $134.3 million in Q3 2025 from $145.8 million in Q2 2025, while long-term debt dropped to $0 from $36.5 million.
  • Cash increased in Q4 2025. Net change in cash and equivalents was a positive $6.1 million, helped by $11.2 million of financing cash inflows.
  • Operating cash burn was better than in some prior periods. Q4 2025 operating cash flow was negative $5.1 million, an improvement from larger losses earlier in 2025 and much better than the worst 2024 quarter.
  • Share count is lower than a year ago. Weighted average basic shares fell to 25.6 million in Q4 2025 from 28.3 million in Q3 2025 and 21.9 million in Q4 2024, which can help per-share metrics if losses narrow.
  • The company remains unprofitable. Q4 2025 net loss was $24.4 million, following a $23.1 million loss in Q3 2025 and a $24.5 million loss in Q2 2025.
  • Revenue data looks unusual and difficult to interpret. Q4 2025 reported total revenue of negative $17.2 million, and prior 2025 quarters showed zero revenue, indicating the underlying business mix may be inconsistent or affected by accounting adjustments.
  • Balance sheet equity is still negative. Total common equity was negative $20.1 million in Q3 2025, improving from negative $25.5 million in Q2 2025 but still signaling financial weakness.
  • Cash interest expense remains meaningful. Celularity paid $731,000 of cash interest in Q4 2025, adding pressure to already weak profitability.
  • Losses remain substantial relative to the company’s scale. Q4 2025 basic EPS was -$0.95, and losses have stayed near the mid-$20 million range in recent quarters.
  • Operating performance has been volatile year over year. Q3 2024 produced a far larger loss of $93.9 million, showing the business can still experience severe swings in results.
  • Debt still matters despite the Q3 2025 improvement. Short-term debt remained $30.3 million in Q3 2025, and total liabilities are still larger than total assets.
  • Asset base has been shrinking. Total assets declined from $143.8 million in Q1 2024 to $114.2 million in Q3 2025, reflecting a smaller balance-sheet footprint.

Bottom line: Celularity has taken some steps in the right direction on debt and cash, but the company still faces major profitability and balance sheet challenges. Investors should view the recent improvement in financing flexibility as helpful, but not as proof of a durable turnaround yet.

07/28/26 02:20 AM ETAI Generated. May Contain Errors.

Celularity Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Celularity's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Celularity's net income appears to be on an upward trend, with a most recent value of -$91.72 million in 2025, falling from $5.88 million in 2019. The previous period was -$57.89 million in 2024. See Celularity's forecast for analyst expectations on what's next for the company.

Over the last 6 years, Celularity's total revenue changed from $3.75 million in 2019 to $0.00 in 2025, a change of -100.0%.

Celularity's total liabilities were at $145.39 million at the end of 2025, a 17.4% increase from 2024, and a 96,470.0% increase since 2018.

In the past 7 years, Celularity's cash and equivalents has ranged from $24.71 thousand in 2018 to $54.31 million in 2020, and is currently $6.18 million as of their latest financial filing in 2025.

Over the last 6 years, Celularity's book value per share changed from 0.14 in 2019 to -1.34 in 2025, a change of -1,065.9%.


Related Companies

Financial statements for NASDAQ:CELU last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
What Elon told his top shareholders in Texas
Late last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
A storm is coming
The U.S. dollar has sunk to near a four-year low, while the Bureau of Economic Analysis prepares a change to h...
Stansberry Research | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel